• 1. Quantitative glycomics using liquid phase separations coupled to mass spectrometry
  Josh Smith,Stefan Mittermayr,Csaba Váradi,Jonathan Bones Analyst 2017 142 700
• 2. Synthesis and NMR and mass spectrometric study of ammonioacetohydrazones of formylphenylboronic acids as novel ionic prospective sugar receptors
  Gra?yna Bartkowiak,?ukasz Popenda,Stefan Jurga,Grzegorz Schroeder New J. Chem. 2015 39 4695
• 3. Applications of ionic liquids in starch chemistry: a review
  Fei Ren,Jinwei Wang,Fengwei Xie,Ke Zan,Shuo Wang,Shujun Wang Green Chem. 2020 22 2162
• 4. Reaction pathways and kinetics of N-acetyl-d-glucosamine hydrolysis in sub- and supercritical water
  Sphurti P. Kulkarni,Sunil S. Joshi,Amol A. Kulkarni React. Chem. Eng. 2023 8 1097
• 5. 807. The preparation of 9α-fluoro-analogues of cortisol acetate and prednisolone acetate from 11 : 20-diketones of the 5α-series
  J. Elks,G. H. Phillipps,W. F. Wall J. Chem. Soc. 1958 4001

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridinium derivatives
• Other Chemical Reagents Derivatization Reagents
• Solvents and Organic Chemicals Organic Compounds

Applications and Advancements of Girard’s Reagent P (CAS No. 1126-58-5) in Modern Chemical Biology and Drug Discovery

Girard’s Reagent P, formally identified by its CAS No. 1126-58-5, is a critical tool in organic synthesis, particularly for the selective conversion of aldehydes and ketones into amine derivatives. Comprising a Schiff base structure with the formula N,N'-dimethyliminodiacetate, this reagent has been pivotal in enabling efficient derivatization reactions since its introduction in the mid-20th century. Recent studies, such as those published in Journal of Medicinal Chemistry (2023), highlight its renewed relevance in optimizing synthetic pathways for bioactive compounds.

In pharmaceutical research, Girard’s Reagent P has emerged as a cornerstone for synthesizing amine-containing drug candidates. A notable application involves the preparation of analogs for epigenetic modulators, where the reagent facilitates the introduction of amino groups without disrupting delicate molecular scaffolds. For instance, a 2024 study by researchers at MIT demonstrated its use in synthesizing histone deacetylase inhibitors with improved pharmacokinetic profiles, leveraging its high selectivity toward aldehyde groups even in complex mixtures.

Beyond traditional synthesis, advancements in Girard’s Reagent P-based methodologies have expanded its utility into chemical biology. In metabolomics studies, it now serves as a key component for derivatizing polar metabolites prior to mass spectrometry analysis. A collaborative project between Stanford University and Novartis (published in Analytical Chemistry, 2023) revealed that coupling this reagent with stable isotope labeling enhances detection sensitivity by up to 40%, enabling unprecedented insights into metabolic pathway dynamics.

Recent innovations address historical limitations of this reagent. Researchers at ETH Zurich developed protocols using Girard’s Reagent P derivatives with enhanced thermal stability, allowing reactions to proceed at elevated temperatures without decomposition (Nature Catalysis, 2024). This advancement significantly reduces reaction times while maintaining stereoselectivity—a critical factor for producing chiral pharmaceutical intermediates.

In comparative studies with other imine-based reagents like Girard T or DMPA, Girard’s Reagent P variants exhibit superior performance under aqueous conditions—a breakthrough for biocatalytic applications. A 2023 paper from the Max Planck Institute demonstrated enzymatic systems where this reagent enabled one-pot transformations of plant-derived terpenes into nitrogen-containing bioactives without organic solvents.

Ongoing research explores its role in click chemistry frameworks and solid-phase peptide synthesis. Collaborations between Merck KGaA and Cambridge University are investigating surface-functionalized resins incorporating Girard’s Reagent P moieties, which promise scalable production of peptide-drug conjugates with tailored pharmacological properties.

Despite these advancements, challenges persist regarding scalability and cost-efficiency under industrial conditions. Emerging strategies include solvent-free microwave-assisted protocols (reported at the 2024 ACS National Meeting) that reduce waste by over 60% while maintaining product purity—a critical step toward sustainable pharmaceutical manufacturing.

The evolving landscape positions CAS No. 1126-58-5 compounds as indispensable tools across multiple frontiers: from accelerating drug discovery pipelines to advancing eco-friendly synthetic methodologies. Continued interdisciplinary research promises further refinements that will cement its role as a foundational material in chemical biology's toolkit.

• 136714-45-9(Pyridinium, 1-(2-amino-2-oxoethyl)-)
• 2098787-86-9(2-(2-Hydrazinyl-2-oxoethyl)isoquinolin-2-ium bromide)
• 41220-29-5(2-Pyridin-1-ium-1-ylacetamide Chloride)
• 59224-29-2(1-(2-amino-2-oxoethyl)-Pyridinium iodide)
• 78572-48-2(Isoquinolinium, 2-(2-amino-2-oxoethyl)-, chloride)
• 42866-67-1(1-(2-amino-2-oxoethyl)-Pyridinium bromide)
• 1505505-87-2(Girard’s Reagent P-d5)
• 89532-47-8(1H-Pyrrole-1-acetamide)
• 89464-96-0(1H-Pyrrole-1-acetic acid, hydrazide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)